Hospital
Banner Health
Banner Health was paid $8.33M by Medicaid between Nov 2020 and Dec 2024, across 145 billing codes. Its largest line is 99285, emergency room visit (most serious) — 27% of everything it billed.
33Billing provider infoBANNER HEALTH
CHANDLER, AZ 85286
CHANDLER, AZ 85286
33aNPI1972139004assigned 03/20/2020
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.33M
24GClaims262,085
24DCodes billed145
24AFirst – last monthNov 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#44 of 78
Median peer was paid$12.21M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 3,423 | $160K | |
| 2021 | 43,629 | $1.43M | |
| 2022 | 71,170 | $2.23M | |
| 2023 | 77,213 | $2.40M | |
| 2024incomplete | 66,650 | $2.10M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 27% | 5,870 | 5,419 | $2.23M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 10,843 | 9,926 | $1.84M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 7,099 | 6,657 | $1.37M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 15% | 2,309 | 2,223 | $1.27M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 7.4% | 1,962 | 1,833 | $620K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.2% | 2,489 | 2,355 | $353K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.9% | 996 | 953 | $158K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 1,333 | 1,276 | $140K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.2% | 374 | 364 | $96K |
| G0378 | Hospital observation service, per hour | 1.1% | 2,609 | 1,270 | $91K |
| 49083 | <1% | 69 | 25 | $37K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 567 | 382 | $25K |
133 more codes
| 93971 | <1% | 316 | $16K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 113 | $12K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,600 | $8K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,604 | $6K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 183 | $6K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 534 | $5K |
| 96376 | <1% | 2,230 | $5K | |
| 80053 | Comprehensive metabolic panel | <1% | 15,320 | $4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 747 | $4K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 13 | $4K |
| 43235 | <1% | 12 | $3K | |
| 80320 | <1% | 1,715 | $3K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 32 | $3K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 31 | $2K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,782 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,953 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,614 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,078 | $627.04 |
| 70486 | <1% | 12 | $583.01 | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,730 | $542.68 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,197 | $524.94 |
| J3490 | Unclassified drugs | <1% | 11,587 | $523.80 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 483 | $438.02 |
| 71250 | <1% | 34 | $336.61 | |
| 84484 | <1% | 5,415 | $330.72 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,994 | $275.62 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,548 | $271.18 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 155 | $257.76 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,239 | $256.44 |
| 87631 | <1% | 862 | $252.71 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,658 | $228.04 |
| 93976 | <1% | 400 | $221.93 | |
| 73562 | <1% | 246 | $218.03 | |
| 83690 | <1% | 7,289 | $185.63 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,682 | $148.86 |
| 85379 | <1% | 800 | $147.07 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,761 | $131.47 |
| 81025 | <1% | 1,749 | $127.16 | |
| 84703 | <1% | 2,386 | $120.86 | |
| 84702 | <1% | 2,015 | $117.93 | |
| 83735 | <1% | 4,008 | $107.16 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 14,995 | $104.02 |
| 74018 | <1% | 182 | $84.44 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,832 | $69.87 |
| 82947 | <1% | 5,108 | $67.44 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,833 | $62.94 |
| 83880 | <1% | 1,289 | $60.30 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,161 | $56.77 |
| 87186 | <1% | 674 | $54.88 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,762 | $54.75 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 272 | $53.39 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 840 | $52.59 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 636 | $50.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,019 | $48.87 |
| 87088 | <1% | 2,218 | $46.34 | |
| 81001 | <1% | 5,716 | $44.40 | |
| 85027 | <1% | 1,465 | $41.81 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,085 | $37.62 |
| 90715 | <1% | 17 | $36.76 | |
| 87077 | <1% | 975 | $35.03 | |
| 82550 | <1% | 1,419 | $35.03 | |
| 81003 | <1% | 2,762 | $32.95 | |
| 83605 | <1% | 2,811 | $30.63 | |
| 85610 | <1% | 3,083 | $30.27 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 355 | $24.56 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,599 | $24.06 |
| 87040 | <1% | 2,099 | $21.40 | |
| 86850 | <1% | 717 | $20.88 | |
| 85730 | <1% | 206 | $19.62 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 608 | $14.53 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 767 | $12.90 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,513 | $12.38 |
| 87081 | <1% | 117 | $12.20 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,266 | $12.16 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 395 | $11.66 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 884 | $11.16 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 447 | $10.41 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 55 | $9.95 |
| 86901 | <1% | 952 | $9.84 | |
| 86900 | <1% | 759 | $9.52 | |
| 86140 | <1% | 558 | $9.35 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,573 | $7.26 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 792 | $6.50 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 385 | $5.92 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 823 | $4.76 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 16 | $4.46 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 365 | $3.46 |
| J1815 | Injection, insulin, per 5 units | <1% | 542 | $1.20 |
| S0028 | Injection, famotidine, 20 mg | 0% | 351 | $0.00 |
| 87075 | 0% | 85 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 1,052 | $0.00 |
| 85055 | 0% | 84 | $0.00 | |
| 84145 | 0% | 225 | $0.00 | |
| 72100 | 0% | 13 | $0.00 | |
| 73630 | 0% | 208 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 368 | $0.00 |
| 73610 | 0% | 119 | $0.00 | |
| 73030 | 0% | 55 | $0.00 | |
| 96367 | 0% | 45 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 212 | $0.00 |
| 82805 | 0% | 14 | $0.00 | |
| 84100 | 0% | 68 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 54 | $0.00 |
| 82010 | 0% | 30 | $0.00 | |
| 89051 | 0% | 31 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 22 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 28 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 18 | $0.00 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 12 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 14 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 15 | $0.00 |
| A9270 | Non-covered item or service | 0% | 6,840 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 80 | $0.00 |
| 87205 | 0% | 210 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,210 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 38 | $0.00 |
| J8597 | Antiemetic drug, oral, not otherwise specified | 0% | 186 | $0.00 |
| 87070 | 0% | 205 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 51 | $0.00 |
| C1769 | Guide wire | 0% | 15 | $0.00 |
| 82270 | 0% | 12 | $0.00 | |
| 94760 | 0% | 151 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 73 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 71 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 26 | $0.00 |
| 76801 | 0% | 82 | $0.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 12 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 27 | $0.00 |
| 88342 | 0% | 20 | $0.00 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 0% | 12 | $0.00 |
| 84132 | 0% | 15 | $0.00 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 14 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROBERTSON, LAURA (CEO)
| Provider | Location | Paid |
|---|---|---|
| Banner Desert Medical Center | Mesa, AZ | $199.62M |
| Bartlesville Pediatric Occupational Therapy, LLC | Bartlesville, OK | $2.51M |
| Cedar Hill Pediatrics LLC | Brockton, MA | $1.55M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.